Shanghai Pharma finalizes biomedical M&A fund participation

Shanghai Pharmaceuticals Holding Co. (HKEX:2607) announced the finalization of its participation in the Biomedical M&A Fund, initially proposed on January 28, 2025. The company, along with Guotou Pioneer, Tofflon, Junshi Biosciences, Meditrust Health, and other partners, has entered into a partnership agreement, completing the industrial and commercial registration procedures. As of March 26, 2025, the fund’s capital commitments total RMB4,660 million, with RMB1,249 million already paid in. Shanghai Pharma committed RMB1,000 million, representing 21.46% of the total commitment, and has paid in RMB268 million. The Biomedical M&A Fund has also completed filing procedures with the Asset Management Association of China. The fund is named Shanghai Biomedical Merger and Acquisition Equity Investment Partnership (Limited Partnership) and managed by Shangshi Capital. Industrial and Commercial Bank of China Limited serves as custodian.